Wedelolactone

Research use only, not for human use.

Wedelolactone inhibits adipogenic differentiation through ERK pathway, may be a novel inhibitory effect on adipogenic differentiation in hAMSCs.

Wedelolactone inhibits adipogenic differentiation through ERK pathway, may be a novel inhibitory effect on adipogenic differentiation in hAMSCs.(In Vitro):Wedelolactone (0-5 μg/mL; 0-21 d) enhances bone marrow mesenchymal stem cells (BMSC) differentiation towards osteoblasts.Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity and increases β-catenin and runx2 nuclear accumulation in BMSC, and inhibits the effect of RANKL.Wedelolactone (0-5 μg/ml; 60 min) inhibits GSK3β activity and proves GSK3β is the target of wedelolactone.Wedelolactone (0-5 μg/ml; 6 d) inhibits c-src, c-fos and cathepsin k expression level.(In Vivo):Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) decreases bone volumn and trabecular number at the femur after ovarietomy, and prevents the VOX-induced bone loss.

Wedelolactone (0-5 μg/mL; 0-21 d) enhances bone marrow mesenchymal stem cells (BMSC) differentiation towards osteoblasts.Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity and increases β-catenin and runx2 nuclear accumulation in BMSC, and inhibits the effect of RANKL.Wedelolactone (0-5 μg/ml; 60 min) inhibits GSK3β activity and proves GSK3β is the target of wedelolactone.Wedelolactone (0-5 μg/ml; 6 d) inhibits c-src, c-fos and cathepsin k expression level. Cell Differentiation Assay Cell Line:Mouse BMSC Concentration:0-5 μg/mL Incubation Time:0, 6, 9, 12 and 21 days Result:Increased Mouse BMSC into osteoblastic cells and dose-dependently increased the activity of alkaline phosphatase at incubation for 9 days. Western Blot Analysis Cell Line:Mouse BMSC and RAW264.7 cells Concentration:0-5 μg/mL Incubation Time:0-9 days Result:Decreased GSK3β expression level and up-regulated GSK3β phosphorylation, nuclear accumulation of β-catenin and runx2 in BMSC. Inhibited RANKL-induced phosphorylation of NF-κB/p65 and the expression level of c-fos and c-Src.Cell Viability Assay Cell Line:Mouse BMSC Concentration:0.1, 1.25, 2.5, 5 μg/ml Incubation Time:60 min Result:Inhibited GSK3β activity with an IC50 of 21.7 μM weeker than staurosporin which is a GSK3β inhibitor and proved GSK3β is a target.RT-PCR Cell Line:RAW264.7 cells Concentration:0, 0.6, 1.25, 2.5 and 5 μg/mL Incubation Time:6 days Result:Inhibited the expression of osteoclast differentiation related marker genes c-src, c-fos and cathepsin in RAW264.7 cells.

Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) decreases bone volumn and trabecular number at the femur after ovarietomy, and prevents the VOX-induced bone loss. Animal Model:Ovariectomized 9-week-old mice Dosage:10 mg/kg Administration:Intraperitoneal injection; 10 mg/kg every 2 days; for 4 weeks Result:Inhibited osteoclast activity and stimulated osteoblast differentiation to achieved osteoprotective effect.

IKK Inhibitor II

Apoptosis

NF-κB

NF-κB

Cancer

——

524-12-9

314.3

C16H10O7

>98% (HPLC)

Soluble in Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

O=C1C2=C(OC3=CC(O)=C(O)C=C32)C4=C(O)C=C(OC)C=C4O1

6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 1,8,9-trihydroxy-3-methoxy-

(-20℃)

With Ice Pack

≥ 2 years